<div id="readability-page-1"><p>Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) have been given a consensus rating of &#34;Moderate Buy&#34; by the seven research firms that are  covering the stock, MarketBeat Ratings reports. One research analyst  has rated the stock with a sell recommendation, one  has assigned  a hold recommendation and five have assigned  a buy recommendation to  the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $46.6667.</p><div><p><span></span><span>Get <strong>Mineralys Therapeutics</strong> alerts:</span></p></div><ul><li>There's a Lot to Love About Mineralys' Valentine's Day IPO </li></ul><p>Several analysts recently commented on MLYS shares. Wells Fargo &amp; Company increased their price objective on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, November 11th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. The Goldman Sachs Group upped their price objective on Mineralys Therapeutics from $32.00 to $52.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, September 9th. Bank of America lifted their target price on Mineralys Therapeutics from $38.00 to $43.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, August 28th. Finally, HC Wainwright upped their price target on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 12th.</p><p><b>View Our Latest Analysis on Mineralys Therapeutics</b></p><h2>Insider Buying and Selling at Mineralys Therapeutics</h2><p>In related news, Director Alexander M. Gold sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $43.98, for a total value of $659,700.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jon Congleton sold 200,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $45.44, for a total transaction of $9,088,000.00. Following the completion of the sale, the chief executive officer directly owned 631,305 shares of the company's stock, valued at approximately $28,686,499.20. This trade represents a 24.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,416,793 shares of company stock worth $62,019,643. 25.56% of the stock is owned by company insiders. </p><h2>Institutional Trading of Mineralys Therapeutics</h2><p>Several large investors have recently modified their holdings of MLYS. Wellington Management Group LLP grew its stake in  Mineralys Therapeutics by 32.8% during the first quarter. Wellington Management Group LLP now owns 121,557 shares of the company's stock valued at $1,930,000 after acquiring an additional 30,028 shares in the last quarter.  Geode Capital Management LLC grew its position in shares of  Mineralys Therapeutics by 19.0% during the second quarter. Geode Capital Management LLC now owns 954,560 shares of the company's stock valued at $12,917,000 after purchasing an additional 152,560 shares in the last quarter.  Voya Investment Management LLC bought a new stake in shares of  Mineralys Therapeutics in the first quarter worth about $255,000.  Strs Ohio purchased a new stake in shares of  Mineralys Therapeutics in the first quarter worth about $359,000.  Finally, Goldman Sachs Group Inc. boosted its stake in  Mineralys Therapeutics by 166.6% during the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company's stock valued at $4,739,000 after buying an additional 186,480 shares during the last quarter. Institutional investors own  84.46% of the company's stock. </p><h2>Mineralys Therapeutics Stock Down 1.1%</h2><p>Mineralys Therapeutics stock opened at $38.50 on Friday. Mineralys Therapeutics has a twelve month low of $8.24 and a twelve month high of $47.65. The company has a market capitalization of $3.05 billion, a P/E ratio of -13.05 and a beta of 0.40. The stock's 50 day moving average is $41.24 and its 200 day moving average is $26.74. </p><p>Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14.  As a group, equities analysts expect that  Mineralys Therapeutics will post -4.23 EPS for the current year. </p><h2>Mineralys Therapeutics Company Profile</h2> (Get Free Report)<p>Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.</p><h2>See Also</h2><ul><li>Five stocks we like better than Mineralys Therapeutics</li><li>3 Tickers Leading a Meme Stock Revival</li><li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li><li>The Role Economic Reports Play in a Successful Investment Strategy</li><li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li><li>Growth Stocks: What They Are, What They Are Not</li><li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUxZUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUxZUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Mineralys Therapeutics Right Now?</h2><p>Before you consider Mineralys Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.</p><p>While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MLYS

<p>Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has received a "Moderate Buy" consensus rating from seven research firms. Analysts have set an average 12-month target price of $46.67. Recent insider trading includes significant stock sales by the CEO and a director. Institutional investors own 84.46% of the stock. The stock opened at $38.50, with a market cap of $3.05 billion. Mineralys reported a quarterly EPS of ($0.52), beating estimates. The company develops therapies for hypertension and chronic kidney diseases.</p>

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts